Stockreport

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients [Yahoo! Finance]

Annovis Bio, Inc.  (ANVS) 
PDF MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering tran [Read more]